Case Studies: Valeo - Deployer

Strategic Portfolio Expansion

and Partnership Development

Introduction

Valeo Pharma, a specialty pharmaceutical company from Canada, sought to expand its portfolio by identifying innovative prescription products aligned with its focus on neurodegenerative diseases. To achieve this, the company engaged Trifermed to support its search for high-value pharmaceutical assets and to facilitate strategic partnerships for licensing agreements.​

Through Trifermed’s structured approach to portfolio development and strategic partnerships, Valeo Pharma successfully identified and secured an agreement for a novel treatment option for Parkinson’s Disease with Zambon S.p.A., a European pharmaceutical company specializing in central nervous system (CNS) disorders. This collaboration positioned Valeo Pharma as a key player in the Canadian Parkinson’s treatment landscape.

Background

Parkinson’s Disease affects an estimated 100,000 Canadians, with the prevalence expected to rise significantly in the coming decades. Valeo Pharma aimed to address the growing need for innovative treatments by acquiring a product that would complement its existing portfolio and enhance its market presence in Canada.​

The primary objectives were:

  • Identifying high-potential pharmaceutical assets in the CNS therapeutic area.​

  • Establishing a licensing agreement with a reputable partner for market expansion.​

  • Ensuring a structured negotiation process leading to a mutually beneficial partnership.​

Trifermed was engaged to facilitate this process by leveraging its expertise in business development, portfolio strategy, and partnership negotiation.​

Services Provided

  • Portfolio Strategy & Asset Identification

  • Market Intelligence & Asset Scouting

  • Partner Identification & Negotiation Support

Outcomes & Future Development

As a result of Trifermed’s facilitation, Valeo Pharma successfully secured exclusive rights to commercialize the Parkinson’s treatment in Canada. The licensing agreement enabled strengthening the company’s presence in the CNS market with an innovative Parkinson’s therapy.

Link